digestVidSign in
summary

Ben Bikman - “If the goal is to keep insulin low, why is GLP-1 good, since it stimulates insulin production?”

Thumbnail of the video “Ben Bikman - “If the goal is to keep insulin low, why is GLP-1 good, since it stimulates insulin production?””
Community upload. AI output has not been independently verified.
Author: Ben Bikman
Categories: Nutrition Education
Tags: nutrition, education
Views: 2 · Last viewed: 2026-10-14 23:16 UTC

Short Summary

Main recommendation: The speaker argues that GLP-1 drugs such as semaglutide do not stimulate insulin release in humans, so the claim that they raise insulin while reducing appetite is, in his view, not physiologically coherent. He cites a study by Dr. Arie Ostrup, described as head scientist at Novo Nordisk in Denmark, as evidence, though he does not give the title or results in the transcript. The transcript ends before the study is actually shared.

Key Points

  • The speaker frames the question as one that opponents of the low-insulin view have "weaponized" against those who see insulin as central to insulin resistance and weight loss.
  • He argues that raising insulin while reducing food intake would be a "lethal shift": high insulin pushes glucose out of the blood and inhibits ketogenesis, leaving the brain short of both glucose and ketones.
  • He states that GLP-1 drugs in humans "do not stimulate an insulin release," citing a body of literature he calls "hugely confounding."
  • He says he has been discussing the question by email with several people, including Gary Taubes, described as a science reporter and author, and other physicians and scientists.
  • He says he has concerns about GLP-1 weight loss drugs, mainly because he thinks they are overused.

Details Worth Noting

  • Concrete instructions: The transcript gives no step-by-step method for patients or viewers. The only actionable item is that the speaker plans to share the named study with the questioner, Mary, once he has the title (he says he will "put this in and send it").
  • The speaker's claim rests on a single study he intends to share; the transcript does not state its findings in detail, so the claim should be checked against the paper itself.
  • The speaker presents his argument as his own interpretation and says he is not a neutral party in the debate.
  • The transcript is informal and partly unfinished, and includes several off-topic asides, so the core evidence is limited to the study reference.
  • Health-related claims here are the speaker's views on insulin and GLP-1 drugs, not professional medical advice.

Bottom Line

The core dispute is whether GLP-1 drugs raise insulin in humans, and the speaker's answer is no, but the transcript only points to a study rather than presenting its data, so the claim is unverified within the video.